This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Leukocyte Interleukin (LI)
Description: Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors.
CEL-SCI and Teva
In August 2008, CEL-SCI announced that it entered into an exclusive licensing agreement with Teva Pharmaceutical Industries under which CEL-SCI has granted Teva an exclusive license to market and distribute Multikine for Israel and Turkey (the Territory). The licensing agreement is initially restricted to the areas of head and neck cancer. Teva has the right, subject to certain conditions, to extend the licensing agreement to include other cancers during the term of this agreement.
Pursuant to the agreement, Teva will participate in CEL-SCI's upcoming global Phase III clinical trial. Teva will fund a portion of the Phase III clinical study and Teva's clinical group will conduct part of the clinical study in Israel under the auspices of CEL-SCI and its Clinical Research Organization. Teva will also be responsible for registering the product in the Territory. Once Multikine has been approved, CEL-SCI will be responsible for manufacturing the product, while...See full deal structure in Biomedtracker
Partners: Teva Pharmaceutical Industries Ltd. Ergomed PLC Orient Europharma Co., Ltd.
Additional information available to subscribers only: